Long-term efficacy of oral cladribine as a result of immune reconstitution therapy – a case report Case report
Article Sidebar
Published:
Sep 30, 2022
Keywords:
multiple sclerosis, immune reconstitution therapy, cladribine
Main Article Content
Abstract
Multiple sclerosis is a chronic demyelinating disease of the central nervous system. We dispose more and more effective therapies for the disease. One of them is cladribine, an oral drug, acting in the mechanism of immune reconstitution. The article presents a case of a patient with relapsing-remitting multiple sclerosis, treated with cladribine, what led to a long-term remission of the disease. Recommendations for the management of patients who have completed a course of treatment or who have not responded to treatment are also discussed.
Article Details
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav. 2015; 5(9): e00362. http://doi.org/10.1002/brb3.362.
2. Mz.gov.pl. Programy lekowe, program B29.
3. Dobson R, Giovannoni G. Multiple sclerosis – a review. Eur J Neurol. 2019; 26(1): 27-40. http://doi.org/10.1111/ene.13819.
4. Karussis D, Petrou P. Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale. Immunol Res. 2018; 66(6): 642-8. http://doi.org/10.1007/s12026-018-9032-5.
5. Giovannoni G, Mathews J. Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician’s Review. Neurol Ther. 2022; 11: 571-95. http://doi.org/10.1007/s40120-022-00339-7.
6. Deeks ED. Cladribine Tablets: A Review in Relapsing MS. CNS Drugs. 2018; 32(8): 785-96. http://doi.org/10.1007/s40263-018-0562-0.
7. Rejdak K, Stelmasiak Z, Grieb P. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study. Mult Scler Relat Disord. 2019; 27: 117-20. http://doi.org/10.1016/j.msard.2018.10.006.
8. Giovannoni G, Leist T, Aydemir A et al. Long-term Efficacy for Patients Receiving Cladribine Tablets in CLARITY/CLARITY Extension: Primary Results from 9–15 Years of Follow-up in the CLASSIC-MS Study. Presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2021 Congress, DMT69.
9. Meuth SG, Bayas A, Kallmann B et al. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion. Expert Opin Pharmacother. 2020; 21(16): 1965-9. http://doi.org/10.1080/14656566.2020.1792885.
10. European Medicines Agency Assessment Report, cladribine tablets (Mavenclad), June 2017 (access: 15.12.2022).
11. Meuth SG, Bayas A, Kallmann B et al. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4. Expert Opin Pharmacother. 2022. http://doi.org/10.1080/14656566.2022.2106783.
12. Patti F, Visconti A, Capacchione A et al. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Ther Adv Neurol Disord. 2020; 13(13): 1756286420922685.
13. Petracca M, Ruggieri S, Barbuti E et al. Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study. Neurol Ther. 2022; 11(3): 1193-208. http://doi.org/10.1007/s40120-022-00364-6.
14. Stanowisko polskich ekspertów klinicznych w sprawie strategii postępowania podczas leczenia kladrybiną w tabletkach w zależności od stanu klinicznego pacjenta (access: 15.12.2022).
15. Ellenberger D, Frahm N, Flachenecker P et al. Treatment patterns prior to and post cladribine in patients with multiple sclerosis. Eur J Neurol. 2022; 29(suppl 1): 629-30.
16. Meca-Lallana V, García Domínguez JM, López Ruiz R et al. Expert-Agreed Practical Recommendations on the Use of Cladribine. Neurol Ther. 2022; 11(4): 1475-88. http://doi.org/10.1007/s40120-022-00394-0.
2. Mz.gov.pl. Programy lekowe, program B29.
3. Dobson R, Giovannoni G. Multiple sclerosis – a review. Eur J Neurol. 2019; 26(1): 27-40. http://doi.org/10.1111/ene.13819.
4. Karussis D, Petrou P. Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale. Immunol Res. 2018; 66(6): 642-8. http://doi.org/10.1007/s12026-018-9032-5.
5. Giovannoni G, Mathews J. Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician’s Review. Neurol Ther. 2022; 11: 571-95. http://doi.org/10.1007/s40120-022-00339-7.
6. Deeks ED. Cladribine Tablets: A Review in Relapsing MS. CNS Drugs. 2018; 32(8): 785-96. http://doi.org/10.1007/s40263-018-0562-0.
7. Rejdak K, Stelmasiak Z, Grieb P. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study. Mult Scler Relat Disord. 2019; 27: 117-20. http://doi.org/10.1016/j.msard.2018.10.006.
8. Giovannoni G, Leist T, Aydemir A et al. Long-term Efficacy for Patients Receiving Cladribine Tablets in CLARITY/CLARITY Extension: Primary Results from 9–15 Years of Follow-up in the CLASSIC-MS Study. Presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2021 Congress, DMT69.
9. Meuth SG, Bayas A, Kallmann B et al. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion. Expert Opin Pharmacother. 2020; 21(16): 1965-9. http://doi.org/10.1080/14656566.2020.1792885.
10. European Medicines Agency Assessment Report, cladribine tablets (Mavenclad), June 2017 (access: 15.12.2022).
11. Meuth SG, Bayas A, Kallmann B et al. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4. Expert Opin Pharmacother. 2022. http://doi.org/10.1080/14656566.2022.2106783.
12. Patti F, Visconti A, Capacchione A et al. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Ther Adv Neurol Disord. 2020; 13(13): 1756286420922685.
13. Petracca M, Ruggieri S, Barbuti E et al. Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study. Neurol Ther. 2022; 11(3): 1193-208. http://doi.org/10.1007/s40120-022-00364-6.
14. Stanowisko polskich ekspertów klinicznych w sprawie strategii postępowania podczas leczenia kladrybiną w tabletkach w zależności od stanu klinicznego pacjenta (access: 15.12.2022).
15. Ellenberger D, Frahm N, Flachenecker P et al. Treatment patterns prior to and post cladribine in patients with multiple sclerosis. Eur J Neurol. 2022; 29(suppl 1): 629-30.
16. Meca-Lallana V, García Domínguez JM, López Ruiz R et al. Expert-Agreed Practical Recommendations on the Use of Cladribine. Neurol Ther. 2022; 11(4): 1475-88. http://doi.org/10.1007/s40120-022-00394-0.